CervoMed

Yahoo Finance • 5 days ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating the utility of neflamapimod and its ef... Full story

Yahoo Finance • 19 days ago

CervoMed reports Q3 results

* CervoMed press release [https://seekingalpha.com/pr/20300116-cervomed-reports-third-quarter-2025-financial-results-and-provides-corporate-updates] (CRVO [https://seekingalpha.com/symbol/CRVO]): Q3 Net loss was approximately $7.7 millio... Full story

Yahoo Finance • last month

Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The Emerging Growth Conference identifies c... Full story

Yahoo Finance • last month

Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The Emerging Growth Conference identifies c... Full story

Yahoo Finance • last month

CervoMed to Present at the Emerging Growth Conference

BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D.,... Full story

Yahoo Finance • 2 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having Alzheimer’s disease (... Full story

Yahoo Finance • 2 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management wil... Full story

Yahoo Finance • 2 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 2 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising develop... Full story

Yahoo Finance • 3 months ago

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the foll... Full story

Yahoo Finance • 4 months ago

Traders are paying attention to the gapping stocks in Monday's session.

The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT AIM [https://www.chartmill.com/stock/quot... Full story

Yahoo Finance • 4 months ago

What's going on in today's pre-market session

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT HTOOW [https://www.chartm... Full story

Yahoo Finance • 4 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This... Full story

Yahoo Finance • 4 months ago

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:... Full story

Yahoo Finance • 5 months ago

CervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3

CervoMed Inc. (NASDAQ:CRVO) is one of the best-performing NASDAQ stocks according to analysts. On June 10, CervoMed announced a significant addition to its senior leadership team. Dr. Marco Verwijs, PhD, joined CervoMed in June this year a... Full story

Yahoo Finance • 8 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th Int... Full story

Yahoo Finance • 9 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating... Full story

Yahoo Finance • 10 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB stud... Full story